Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71

1.

Concept Drift and Anomaly Detection in Graph Streams.

Zambon D, Alippi C, Livi L.

IEEE Trans Neural Netw Learn Syst. 2018 Nov;29(11):5592-5605. doi: 10.1109/TNNLS.2018.2804443. Epub 2018 Mar 9.

PMID:
29994077
2.

Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study.

Pérez de Isla L, Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, Miramontes JP, Fuentes F, Gómez de Diego JJ, González-Estrada A, Mata N, Saltijeral A, Barreiro M, Tomás M, de Andrés R, Argüeso R, Serrano Gotarredona MP, Navarro Herrero S, Perea Palazón RJ, de Caralt TM, Suárez de Centi LA, Zhilina S, Espejo Pérez S, Padró T, Mata P; SAFEHEART investigators.

J Clin Lipidol. 2018 Jul - Aug;12(4):948-957. doi: 10.1016/j.jacl.2018.04.003. Epub 2018 Apr 17.

PMID:
29753733
3.

Three zinc(II) and cadmium(II) complexes containing 4-amino-3,5-bis(pyridin-2-yl)-1,2,4-triazole and polynitrile ligands: synthesis, molecular and supramolecular structures, and photoluminescence properties.

Setifi Z, Zambon D, Setifi F, El-Ghozzi M, Mahiou R, Glidewell C.

Acta Crystallogr C Struct Chem. 2017 Sep 1;73(Pt 9):674-681. doi: 10.1107/S2053229617011391. Epub 2017 Aug 7.

PMID:
28872063
4.

Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study).

Pérez de Isla L, Alonso R, Mata N, Fernández-Pérez C, Muñiz O, Díaz-Díaz JL, Saltijeral A, Fuentes-Jiménez F, de Andrés R, Zambón D, Piedecausa M, Cepeda JM, Mauri M, Galiana J, Brea Á, Sanchez Muñoz-Torrero JF, Padró T, Argueso R, Miramontes-González JP, Badimón L, Santos RD, Watts GF, Mata P.

Circulation. 2017 May 30;135(22):2133-2144. doi: 10.1161/CIRCULATIONAHA.116.024541. Epub 2017 Mar 8.

PMID:
28275165
5.

Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry.

Saltijeral A, Pérez de Isla L, Alonso R, Muñiz O, Díaz-Díaz JL, Fuentes F, Mata N, de Andrés R, Díaz-Soto G, Pastor J, Pinilla JM, Zambón D, Pinto X, Badimón L, Mata P; SAFEHEART Investigators.

Rev Esp Cardiol (Engl Ed). 2017 Jun;70(6):444-450. doi: 10.1016/j.rec.2016.10.010. Epub 2016 Nov 29. English, Spanish.

PMID:
27913073
6.

PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia.

Alonso R, Mata P, Muñiz O, Fuentes-Jimenez F, Díaz JL, Zambón D, Tomás M, Martin C, Moyon T, Croyal M, Thedrez A, Lambert G.

Atherosclerosis. 2016 Nov;254:249-253. doi: 10.1016/j.atherosclerosis.2016.08.038. Epub 2016 Aug 27.

PMID:
27594539
7.

Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study).

Pérez de Isla L, Alonso R, Mata N, Saltijeral A, Muñiz O, Rubio-Marin P, Diaz-Diaz JL, Fuentes F, de Andrés R, Zambón D, Galiana J, Piedecausa M, Aguado R, Mosquera D, Vidal JI, Ruiz E, Manjón L, Mauri M, Padró T, Miramontes JP, Mata P; SAFEHEART Investigators.

Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):2004-10. doi: 10.1161/ATVBAHA.116.307514. Epub 2016 Jul 21.

PMID:
27444203
8.

Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.

Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, Fuentes F, Diaz-Diaz JL, de Andrés R, Zambón D, Rubio-Marin P, Barba-Romero MA, Saenz P, Sanchez Muñoz-Torrero JF, Martinez-Faedo C, Miramontes-Gonzalez JP, Badimón L, Mata P; SAFEHEART Investigators.

J Am Coll Cardiol. 2016 Mar 22;67(11):1278-85. doi: 10.1016/j.jacc.2016.01.008.

9.

Erectile dysfunction and cardiovascular risk factors in a Mediterranean diet cohort.

Ramírez R, Pedro-Botet J, García M, Corbella E, Merino J, Zambón D, Corbella X, Pintó X; Xarxa de Unitats de Lípids i Arteriosclerosi (XULA) Investigators Group.

Intern Med J. 2016 Jan;46(1):52-6. doi: 10.1111/imj.12937.

PMID:
26482327
10.

Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study.

Fuentes F, Alcala-Diaz JF, Watts GF, Alonso R, Muñiz O, Díaz-Díaz JL, Mata N, Sanchez Muñoz-Torrero JF, Brea Á, Galiana J, Figueras R, Aguado R, Piedecausa M, Cepeda JM, Vidal JI, Rodríguez-Cantalejo F, López-Miranda J, Mata P; SAFEHEART Investigators.

Int J Cardiol. 2015 Dec 15;201:79-84. doi: 10.1016/j.ijcard.2015.07.107. Epub 2015 Aug 5.

PMID:
26296047
11.

Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation.

Alonso R, Andres E, Mata N, Fuentes-Jiménez F, Badimón L, López-Miranda J, Padró T, Muñiz O, Díaz-Díaz JL, Mauri M, Ordovás JM, Mata P; SAFEHEART Investigators.

J Am Coll Cardiol. 2014 May 20;63(19):1982-9. doi: 10.1016/j.jacc.2014.01.063. Epub 2014 Mar 13.

12.

Early diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes.

Alonso R, Mata P, Zambón D, Mata N, Fuentes-Jiménez F.

Expert Rev Cardiovasc Ther. 2013 Mar;11(3):327-42. doi: 10.1586/erc.13.7. Review.

PMID:
23469913
13.

Quality of life in a cohort of familial hypercholesterolemia patients from the south of Europe.

Mata N, Alonso R, Banegas JR, Zambón D, Brea A, Mata P.

Eur J Public Health. 2014 Apr;24(2):221-5. doi: 10.1093/eurpub/cks174. Epub 2012 Dec 22.

PMID:
23264649
14.

Could metabolic syndrome, lipodystrophy, and aging be mesenchymal stem cell exhaustion syndromes?

Mansilla E, Díaz Aquino V, Zambón D, Marin GH, Mártire K, Roque G, Ichim T, Riordan NH, Patel A, Sturla F, Larsen G, Spretz R, Núñez L, Soratti C, Ibar R, van Leeuwen M, Tau JM, Drago H, Maceira A.

Stem Cells Int. 2011;2011:943216. doi: 10.4061/2011/943216. Epub 2011 Jun 13.

15.

Prevalence of metabolic syndrome and cardiovascular disease in a hypertriglyceridemic population.

Ascaso JF, Millán J, Mateo-Gallego R, Ruiz A, Suarez-Tembra M, Borrallo RM, Zambon D, Gonzalez-Santos P, Peres-de-Juan M, Ros E; Hypertriglyceridemia Registry of Spanish Arteriosclerosis Society.

Eur J Intern Med. 2011 Apr;22(2):177-81. doi: 10.1016/j.ejim.2010.12.011. Epub 2011 Jan 14.

PMID:
21402249
16.

Higher incidence of mild cognitive impairment in familial hypercholesterolemia.

Zambón D, Quintana M, Mata P, Alonso R, Benavent J, Cruz-Sánchez F, Gich J, Pocoví M, Civeira F, Capurro S, Bachman D, Sambamurti K, Nicholas J, Pappolla MA.

Am J Med. 2010 Mar;123(3):267-74. doi: 10.1016/j.amjmed.2009.08.015.

17.

KPr(PO(3))(4).

Oudahmane A, Daoud M, Tanouti B, Avignant D, Zambon D.

Acta Crystallogr Sect E Struct Rep Online. 2010 Jul 14;66(Pt 8):i59-i60. doi: 10.1107/S1600536810026942.

18.

Dipotassium dialuminium cyclo-octa-phosphate.

Oudahmane A, Avignant D, Zambon D.

Acta Crystallogr Sect E Struct Rep Online. 2010 Jun 5;66(Pt 7):i49-i50. doi: 10.1107/S1600536810020751.

19.

Sodium terbium(III) polyphosphate.

Oudahmane A, Daoud M, Tanouti B, Avignant D, Zambon D.

Acta Crystallogr Sect E Struct Rep Online. 2010 Mar 24;66(Pt 4):i28-i29. doi: 10.1107/S1600536810010093.

20.

Lutetium(III) cyclo-tetra-phosphate.

Mbarek A, Fourati M, Zambon D, Avignant D.

Acta Crystallogr Sect E Struct Rep Online. 2010 May 8;66(Pt 6):i46. doi: 10.1107/S1600536810016363.

Supplemental Content

Loading ...
Support Center